552 related articles for article (PubMed ID: 24286296)
1. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
2. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
Ciccia F; Guggino G; Rizzo A; Alessandro R; Carubbi F; Giardina A; Cipriani P; Ferrante A; Cannizzaro A; Giacomelli R; Triolo G
Rheumatology (Oxford); 2014 Jul; 53(7):1313-20. PubMed ID: 24602921
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
[TBL] [Abstract][Full Text] [Related]
4. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
6. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.
Pontarini E; Sciacca E; Grigoriadou S; Rivellese F; Lucchesi D; Fossati-Jimack L; Coleby R; Chowdhury F; Calcaterra F; Tappuni A; Lewis MJ; Fabris M; Quartuccio L; Bella SD; Bowman S; Pitzalis C; Mavilio D; De Vita S; Bombardieri M
Front Immunol; 2021; 12():706737. PubMed ID: 34594326
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
8. CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome.
Jin L; Yu D; Li X; Yu N; Li X; Wang Y; Wang Y
Int J Clin Exp Pathol; 2014; 7(5):1988-96. PubMed ID: 24966908
[TBL] [Abstract][Full Text] [Related]
9. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
11. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
Alunno A; Carubbi F; Bistoni O; Caterbi S; Bartoloni E; Di Benedetto P; Cipriani P; Giacomelli R; Gerli R
Clin Exp Immunol; 2016 Jun; 184(3):284-92. PubMed ID: 26814615
[TBL] [Abstract][Full Text] [Related]
12. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
[TBL] [Abstract][Full Text] [Related]
13. The role of salivary gland histopathology in primary Sjögren's syndrome: promises and pitfalls.
Kroese FGM; Haacke EA; Bombardieri M
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):222-233. PubMed ID: 30156550
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
15. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
16. Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome.
Chatzis L; Goules AV; Stergiou IE; Voulgarelis M; Tzioufas AG; Kapsogeorgou EK
Front Immunol; 2021; 12():705079. PubMed ID: 34484201
[TBL] [Abstract][Full Text] [Related]
17. Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.
Lisi S; Sisto M; D'Amore M; Lofrumento DD
Int Immunol; 2015 Apr; 27(4):183-94. PubMed ID: 25381666
[TBL] [Abstract][Full Text] [Related]
18. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
19. Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis.
Souza FB; Porfírio GJ; Andriolo BN; Albuquerque JV; Trevisani VF
PLoS One; 2016; 11(3):e0150749. PubMed ID: 26998607
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
